See more : Grupo Financiero Inbursa, S.A.B. de C.V. (GPFOY) Income Statement Analysis – Financial Results
Complete financial analysis of Amyris, Inc. (AMRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amyris, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- Thesis Gold Inc. (TAU.V) Income Statement Analysis – Financial Results
- Eurofins Scientific SE (ESF.VI) Income Statement Analysis – Financial Results
- ConnectOne Bancorp, Inc. (CNOB) Income Statement Analysis – Financial Results
- Changshu Fengfan Power Equipment Co., Ltd. (601700.SS) Income Statement Analysis – Financial Results
- World Chess PLC (CHSS.L) Income Statement Analysis – Financial Results
Amyris, Inc. (AMRS)
About Amyris, Inc.
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 269.85M | 341.82M | 173.14M | 152.56M | 80.42M | 143.45M | 77.19M | 34.15M | 43.27M | 41.12M | 73.69M | 146.99M | 80.31M | 64.61M | 13.89M |
| Cost of Revenue | 258.67M | 155.14M | 87.81M | 76.19M | 38.91M | 63.83M | 56.68M | 37.37M | 33.20M | 38.25M | 77.31M | 155.62M | 70.52M | 60.43M | 10.36M |
| Gross Profit | 11.18M | 186.68M | 85.33M | 76.37M | 41.51M | 79.62M | 20.51M | -3.22M | 10.07M | 2.87M | -3.62M | -8.62M | 9.80M | 4.18M | 3.53M |
| Gross Profit Ratio | 4.14% | 54.61% | 49.28% | 50.06% | 51.62% | 55.50% | 26.58% | -9.43% | 23.27% | 6.97% | -4.91% | -5.87% | 12.20% | 6.47% | 25.40% |
| Research & Development | 110.22M | 94.29M | 71.68M | 71.46M | 68.69M | 56.84M | 51.41M | 44.64M | 49.66M | 56.07M | 73.63M | 87.32M | 55.25M | 38.26M | 30.31M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 493.63M | 257.81M | 137.07M | 126.59M | 86.92M | 63.03M | 47.72M | 56.26M | 55.44M | 57.05M | 78.72M | 83.23M | 40.39M | 23.56M | 16.62M |
| Other Expenses | 0.00 | -38.07M | -89.16M | -20.15M | 1.36M | -956.00K | -45.37M | -114.18M | -30.00M | -20.86M | -45.63M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 603.84M | 352.10M | 208.75M | 198.05M | 155.61M | 119.88M | 99.13M | 105.62M | 105.10M | 113.12M | 152.35M | 170.55M | 95.64M | 61.82M | 46.93M |
| Cost & Expenses | 862.51M | 507.24M | 296.56M | 274.23M | 194.52M | 183.71M | 155.81M | 143.00M | 138.30M | 151.37M | 229.66M | 326.16M | 166.16M | 122.25M | 57.29M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 258.00K | 264.00K | 387.00K | 162.00K | 1.47M | 1.54M | 1.54M | 448.00K | 1.38M |
| Interest Expense | 24.73M | 25.61M | 47.95M | 58.67M | 39.27M | 36.16M | 37.63M | 78.85M | 28.95M | 9.11M | 4.93M | 1.54M | 1.44M | 1.22M | 377.00K |
| Depreciation & Amortization | 27.27M | -25.38M | -77.04M | -20.15M | 4.92M | 11.36M | 11.37M | 12.92M | 14.97M | 16.64M | 14.57M | 11.08M | 7.28M | 5.78M | 2.63M |
| EBITDA | -514.21M | -190.80M | -200.46M | -141.83M | -112.74M | -41.22M | -115.83M | -118.46M | -225.62M | -5.61M | -200.13M | -166.55M | -81.53M | -51.42M | -39.40M |
| EBITDA Ratio | -190.55% | -55.82% | -115.78% | -92.97% | -140.19% | -28.73% | -150.05% | -346.86% | -521.36% | -13.64% | -271.56% | -113.31% | -101.51% | -79.58% | -283.58% |
| Operating Income | -592.67M | -165.42M | -123.42M | -121.67M | -120.95M | -40.26M | -85.92M | -148.53M | -99.83M | -119.62M | -201.82M | -179.17M | -83.79M | -63.41M | -43.40M |
| Operating Income Ratio | -219.63% | -48.39% | -71.29% | -79.76% | -150.40% | -28.07% | -111.31% | -434.90% | -230.69% | -290.90% | -273.86% | -121.89% | -104.33% | -98.14% | -312.41% |
| Total Other Income/Expenses | 54.04M | -106.89M | -200.43M | -120.46M | -28.16M | -36.84M | -10.86M | -69.05M | 102.49M | -116.14M | -3.23M | 213.00K | 2.96M | -1.39M | 857.00K |
| Income Before Tax | -538.63M | -272.31M | -323.85M | -242.14M | -211.35M | -77.10M | -86.78M | -217.58M | 2.66M | -235.75M | -205.05M | -178.96M | -80.83M | -64.80M | -42.54M |
| Income Before Tax Ratio | -199.60% | -79.67% | -187.05% | -158.72% | -262.81% | -53.75% | -112.42% | -637.09% | 6.15% | -573.35% | -278.25% | -121.75% | -100.64% | -100.30% | -306.24% |
| Income Tax Expense | -2.70M | -8.11M | 293.00K | 629.00K | -50.95M | 295.00K | 553.00K | 468.00K | 495.00K | -847.00K | 981.00K | 552.00K | -3.98M | 877.00K | -207.00K |
| Net Income | -535.93M | -264.20M | -324.14M | -242.77M | -211.35M | -77.39M | -87.33M | -217.95M | 2.29M | -235.11M | -205.14M | -178.87M | -81.87M | -64.46M | -41.86M |
| Net Income Ratio | -198.60% | -77.29% | -187.22% | -159.13% | -262.81% | -53.95% | -113.14% | -638.16% | 5.28% | -571.78% | -278.37% | -121.69% | -101.94% | -99.77% | -301.35% |
| EPS | -1.58 | -0.90 | -1.59 | -2.39 | -3.50 | -2.40 | -5.49 | -25.75 | 0.45 | -46.73 | -54.25 | -59.89 | -82.75 | -203.42 | -124.74 |
| EPS Diluted | -1.58 | -0.90 | -1.59 | -2.39 | -3.50 | -2.40 | -4.95 | -25.75 | 0.28 | -46.73 | -54.25 | -59.89 | -82.75 | -203.42 | -124.74 |
| Weighted Avg Shares Out | 339.33M | 292.34M | 203.60M | 101.37M | 60.36M | 32.25M | 15.90M | 8.46M | 5.23M | 5.03M | 3.78M | 2.99M | 989.36K | 316.87K | 335.61K |
| Weighted Avg Shares Out (Dil) | 339.33M | 292.67M | 203.60M | 101.37M | 60.36M | 32.25M | 17.64M | 8.46M | 8.12M | 5.03M | 3.78M | 2.99M | 989.36K | 316.87K | 335.61K |
Amyris, Inc. (AMRS) CEO John Melo on Q1 2022 Results - Earnings Call Transcript
Amyris, Inc. (NASDAQ:AMRS ) Q1 2022 Results Conference Call May 10, 2022 9:00 AM ET Company Participants John Melo - President and Chief Executive Officer Han Kieftenbeld - Chief Financial Officer Conference Call Participants Colin Rusch - Oppenheimer Steven Mah...
Amyris, Inc. (AMRS) Reports Q1 Loss, Misses Revenue Estimates
Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -54.17% and 11.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for May 2nd
ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022
Amryis Update: Building Value One Brick At A Time
2022 is the year of the “Brick” for Amyris as it completes construction of the World's Largest Fermentation Plant, Consumer Production Facilities, and entry into global “Brick-and-Mortar” Retail Chain Stores. Amyris continues to achieve scale across Geographies, Retail Partners, Brands,...
New Strong Sell Stocks for March 24th
GHM, AMRS, and GDOT have been added to the Zacks Rank #5 (Strong Sell) List on March 24, 2022
Will These Penny Stocks Explode in April? 3 to Watch This Week
Which penny stocks are you watching in April? The post Will These Penny Stocks Explode in April?
Amyris: JVN Could Be Their Most Valuable Brand Yet
JVN Hair is a haircare brand that Amyris launched in 2021. The products are based around hemisqualane and the brand is fronted by Jonathan Van Ness.
Amyris (AMRS) Q4 Earnings Lag Estimates, Sales Fall Y/Y
Amyris (AMRS) sees strong revenues in its consumer segment in Q4 driven by the accelerated growth of its consumer brands.
Amyris, Inc. (AMRS) CEO John Melo on Q4 2021 Results - Earnings Call Transcript
Amyris, Inc. (AMRS) CEO John Melo on Q4 2021 Results - Earnings Call Transcript
Amyris, Inc. (AMRS) Gains But Lags Market: What You Should Know
Amyris, Inc. (AMRS) closed at $3.96 in the latest trading session, marking a +0.25% move from the prior day.
Source: https://incomestatements.info
Category: Stock Reports